| First Author | Chew HY | Year | 2020 |
| Journal | Cell | Volume | 180 |
| Issue | 5 | Pages | 895-914.e27 |
| PubMed ID | 32142680 | Mgi Jnum | J:348112 |
| Mgi Id | MGI:7627208 | Doi | 10.1016/j.cell.2020.02.019 |
| Citation | Chew HY, et al. (2020) Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies. Cell 180(5):895-914.e27 |
| abstractText | A safe and controlled manipulation of endocytosis in vivo may have disruptive therapeutic potential. Here, we demonstrate that the anti-emetic/anti-psychotic prochlorperazine can be repurposed to reversibly inhibit the in vivo endocytosis of membrane proteins targeted by therapeutic monoclonal antibodies, as directly demonstrated by our human tumor ex vivo assay. Temporary endocytosis inhibition results in enhanced target availability and improved efficiency of natural killer cell-mediated antibody-dependent cellular cytotoxicity (ADCC), a mediator of clinical responses induced by IgG1 antibodies, demonstrated here for cetuximab, trastuzumab, and avelumab. Extensive analysis of downstream signaling pathways ruled out on-target toxicities. By overcoming the heterogeneity of drug target availability that frequently characterizes poorly responsive or resistant tumors, clinical application of reversible endocytosis inhibition may considerably improve the clinical benefit of ADCC-mediating therapeutic antibodies. |
